Analysts Offer Predictions for Cingulate FY2026 Earnings

Cingulate Inc. (NASDAQ:CING) – Investment analysts at Zacks Research reduced their FY2026 earnings estimates for Cingulate in a research report issued to clients and investors on Tuesday, May 19th. Zacks Research analyst J. Vandermosten now expects that the company will earn ($2.42) per share for the year, down from their prior estimate of ($1.43). The consensus estimate for Cingulate’s current full-year earnings is ($2.19) per share. Zacks Research also issued estimates for Cingulate’s FY2027 earnings at ($1.55) EPS.

Other analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cingulate in a report on Monday, April 20th. Ascendiant Capital Markets dropped their price objective on shares of Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Roth Mkm reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Cingulate in a report on Tuesday. Finally, Wall Street Zen cut shares of Cingulate from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $32.50.

Cingulate Stock Up 2.4%

CING stock opened at $4.74 on Friday. Cingulate has a fifty-two week low of $3.20 and a fifty-two week high of $11.89. The firm’s 50-day simple moving average is $6.04 and its 200 day simple moving average is $5.32. The stock has a market cap of $62.93 million, a PE ratio of -1.12 and a beta of -0.81.

Cingulate (NASDAQ:CING) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42).

Hedge Funds Weigh In On Cingulate

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after buying an additional 5,543 shares during the period. Soltis Investment Advisors LLC acquired a new position in Cingulate during the 4th quarter valued at about $43,000. XTX Topco Ltd acquired a new position in Cingulate during the 2nd quarter valued at about $45,000. Quadrature Capital Ltd acquired a new position in Cingulate during the 4th quarter valued at about $66,000. Finally, Chicago Partners Investment Group LLC acquired a new position in Cingulate during the 1st quarter valued at about $116,000. Institutional investors and hedge funds own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.